基于混合PET/MR的静态18F-FET PET与DSC-PWI预测IDH和1p/19q状态定义的胶质瘤
回顾性纳入52例新诊断胶质瘤患者,在混合PET/MR上行静态18F-FET PET和DSC-PWI,评估肿瘤/脑比值(TBR)与标准化CBV(nCBV)对2016年WHO分类下胶质瘤分级及IDH突变、1p/19q共缺失状态的预测价值。TBRmax与nCBVmean联合对IDH突变型星形细胞瘤与IDH野生型胶质母细胞瘤的鉴别预测性能最佳(AUC 0.903),但各参数对少突胶质细胞瘤与星形细胞瘤的鉴别均无统计学意义。
要点
- nCBVmean对低级别与高级别胶质瘤的鉴别AUC最高(0.920)。
- TBRmax与nCBVmean联合鉴别IDH突变型星形细胞瘤与IDH野生型胶质母细胞瘤的AUC为0.903。
- 仅nCBVmean能区分IDH突变伴1p/19q共缺失的少突胶质细胞瘤与IDH野生型胶质母细胞瘤(AUC 0.829)。
关键影像表现/征象
- TBRmean、TBRmax、nCBVmean和nCBVmax在低级别与高级别胶质瘤间存在差异。
- TBRmax和nCBVmean在IDH突变与未突变胶质瘤间差异有统计学意义(p=0.032和p=0.010)。
- TBRmean、TBRmax和nCBVmean可区分IDH野生型胶质母细胞瘤与IDH突变型星形细胞瘤(p=0.049、0.034和0.029)。
诊断标准与关键数值
- nCBVmean鉴别低级别与高级别胶质瘤的AUC为0.920,为各参数中最高。
- TBRmax联合nCBVmean预测IDH突变型星形细胞瘤与IDH野生型胶质母细胞瘤的AUC为0.903,为最佳预测性能。
- nCBVmean区分IDH突变伴1p/19q共缺失的少突胶质细胞瘤与IDH野生型胶质母细胞瘤的AUC为0.829(p<0.001)。
- 各参数均不能区分少突胶质细胞瘤与星形细胞瘤。
临床应用与阅片要点
- 静态18F-FET PET与DSC-PWI参数可能有助于无创预测胶质瘤分级和IDH突变状态。
- TBRmax联合nCBVmean可能改善IDH突变型星形细胞瘤与IDH野生型胶质母细胞瘤的鉴别。
- FET PET与CBV在识别少突胶质细胞瘤方面可能有限。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate the predictive value of static O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET) and cerebral blood volume (CBV) for glioma grading and determining isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion status.
METHODS: Fifty-two patients with newly diagnosed gliomas who underwent simultaneous 18F-FET PET and dynamic susceptibility contrast perfusion-weighted imaging (DSC-PWI) examinations on hybrid PET/MR were retrospectively enrolled. The mean and max tumor-to-brain ratio (TBR) and normalized CBV (nCBV) were calculated based on whole tumor volume segmentations with reference to PET/MR images. The predictive efficacy of FET PET and CBV in glioma according to the 2016 World Health Organization (WHO) classification was evaluated by receiver operating characteristic curve analyses with the area under the curve (AUC).
RESULTS: TBRmean, TBRmax, nCBVmean, and nCBVmax differed between low- and high-grade gliomas, with the highest AUC of nCBVmean (0.920). TBRmax and nCBVmean showed significant differences between gliomas with and without IDH mutation (p = 0.032 and 0.010, respectively). Furthermore, TBRmean, TBRmax, and nCBVmean discriminated between IDH-wildtype glioblastomas and IDH-mutated astrocytomas (p = 0.049, 0.034 and 0.029, respectively). The combination of TBRmax and nCBVmean showed the best predictive performance (AUC, 0.903). Only nCBVmean differentiated IDH-mutated with 1p/19q codeletion oligodendrogliomas from IDH-wildtype glioblastomas (p < 0.001) (AUC, 0.829), but none of the parameters discriminated between oligodendrogliomas and astrocytomas.
CONCLUSIONS: Both FET PET and DSC-PWI might be non-invasive predictors for glioma grades and IDH mutation status. FET PET combined with CBV could improve the differentiation of IDH-mutated astrocytomas and IDH-wildtype glioblastomas. However, FET PET and CBV might be limited for identifying oligodendrogliomas.
KEY POINTS: • Static 18F-FET PET and DSC-PWI parameters differed between low- and high-grade gliomas, with the highest AUC of the mean value of normalized CBV. • Static 18F-FET PET and DSC-PWI parameters based on hybrid PET/MR showed predictive value in identifying glioma IDH mutation subtypes, which have gained importance for both determining the diagnosis and prognosis of gliomas according to the 2016 WHO classification. • Static 18F-FET PET and DSC-PWI parameters have limited potential in differentiating IDH-mutated with 1p/19q codeletion oligodendrogliomas from IDH-wildtype glioblastomas or IDH-mutated astrocytomas.
引用
- Song S, Wang L, Yang H, et al. Static 18F-FET PET and DSC-PWI based on hybrid PET/MR for the prediction of gliomas defined by IDH and 1p/19q status. Eur Radiol. 2020. PMID: 33211141. doi:10.1007/s00330-020-07470-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。